Wordt geladen...
Experience with ospemifene in patients with vulvar and vaginal atrophy and a history of breast cancer: case studies
Women with breast cancer are at a higher risk of developing vulvar and vaginal atrophy (VVA), a major component of the genitourinary syndrome of menopause, due to the combined estrogen-depleting effects of chemotherapy, adjuvant hormone therapy, and menopause. Ospemifene is approved to treat VVA in...
Bewaard in:
| Gepubliceerd in: | Drugs Context |
|---|---|
| Hoofdauteurs: | , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BioExcel Publishing Ltd
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7337590/ https://ncbi.nlm.nih.gov/pubmed/32670380 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.2020-3-4 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|